Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. Amphastar Pharmaceuticals is most often covered alongside Eli Lilly, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 3.2 across the same-window beat baseline.
Last mentioned: Feb 27, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. Amphastar Pharmaceuticals is most often covered alongside Eli Lilly, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 3.2 across the same-window beat baseline. Their average consequence score of 5 runs below the beat's 5.7 for that window. We currently track 1 Healthcare story that mention Amphastar Pharmaceuticals, all published on February 27, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 29 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Amphastar Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Amphastar Pharmaceuticals (AMPH) has released its financial results for the fourth quarter and full year of 2025, marking a critical milestone in its transition toward a proprietary-led product portfolio. The results highlight the continued performance of Baqsimi and Primatene Mist as the primary drivers of the company's revenue growth and margin expansion.
Source: hawaiitelegraph.com · californiatelegraph.com
Amphastar Pharmaceuticals is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
